Zotarolimus
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326662

CAS#: 221877-54-9

Description: Zotarolimus, also known as ABT-578 and A-179578, is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. Medtronic are using zotarolimus as the anti-proliferative agent in the polymer coating of their Endeavor and Resolute products.


Price and Availability

Size
Price

200mg
USD 2650
2g
USD 7950
Size
Price

500mg
USD 3650
5g
USD 16950
Size
Price

1g
USD 4850

Zotarolimus, purity > 95%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 326662
Name: Zotarolimus
CAS#: 221877-54-9
Chemical Formula: C52H79N5O12
Exact Mass: 965.5725
Molecular Weight: 966.227
Elemental Analysis: C, 64.64; H, 8.24; N, 7.25; O, 19.87


Synonym: A-179578; A 179578; A179578; ABT578; ABT-578; ABT 578; Endeavor; Zotarolimus; Rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-.

IUPAC/Chemical Name: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-3-{(1R)-2-[(1S,3R,4S)-3-methoxy-4-(1H-tetrazol-1-yl)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-heptadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone

InChi Key: CGTADGCBEXYWNE-JUKNQOCSSA-N

InChi Code: InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1

SMILES Code: O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)CC[C@@](O2)([H])C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C([C@H](OC)[C@H](O)/C(C)=C/[C@H]3C)=O)=O)=O)O[C@H]([C@H](C)C[C@H]4C[C@@H](OC)[C@@H](N5N=NN=C5)CC4)CC3=O


Technical Data

Appearance:
Solid powder

Purity:
>95% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Rheude T, Ibrahim T, Massberg S, Laugwitz KL, Kastrati A, Byrne RA; ISAR-TEST-5 Investigators. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. JACC Cardiovasc Interv. 2016 Apr 25;9(8):784-92. doi: 10.1016/j.jcin.2016.01.009. Epub 2016 Mar 23. PubMed PMID: 27017366.

2: Markovic S, Lützner M, Rottbauer W, Wöhrle J. Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions. Catheter Cardiovasc Interv. 2016 Mar 4. doi: 10.1002/ccd.26482. [Epub ahead of print] PubMed PMID: 26945903.

3: Lin L, Jin C, Wei X, Li H, Shi J, Wu S, Yang X, Qi X. Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heart disease between diabetic and non-diabetic patients. Int J Clin Exp Med. 2015 Nov 15;8(11):20813-20. eCollection 2015. PubMed PMID: 26885005; PubMed Central PMCID: PMC4723850.

4: Poorhoseini HR, Kassaian SE, Hoseini K, Saroukhani S, Salarifar M, Alidoosti M, Nematipour E, Haji-Zeinali AM, Amirzadegan A, Seyyed Mohammadzadeh MH, Khadem Vatan K, Aghajani H, Sheikh Fathollahi M, Farrokh-Eslamlou H. Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry. Ther Adv Cardiovasc Dis. 2016 Feb 7. pii: 1753944716629868. [Epub ahead of print] PubMed PMID: 26857928.

5: Di Santo P, Simard T, Ramirez FD, Pourdjabbar A, Harnett DT, Singh K, Moreland R, Chong AY, Dick A, Labinaz M, Froeschl M, Froeschl M, Le May MR, So DY, Hibbert B. Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents. Clin Invest Med. 2015 Oct 7;38(5):E296-304. PubMed PMID: 26854891.

6: Iqbal MB, Nadra IJ, Din JN, Hendry C, Ding L, Fung A, Aymong E, Chan AW, Hodge S, Robinson SD, Della Siega A; British Columbia Cardiac Registry Investigators. Prognostic Significance of Polymer Coatings in Zotarolimus-Eluting Stents. Am J Cardiol. 2016 Mar 1;117(5):735-42. doi: 10.1016/j.amjcard.2015.11.056. Epub 2015 Dec 13. PubMed PMID: 26796194.

7: Nishimoto Y, Matsuo K, Ueda Y, Sugihara R, Hirata A, Murakami A, Kashiwase K, Higuchi Y, Yasumura Y. Angioscopic Comparison of Resolute and Endeavor Zotarolimus-Eluting Stents. Circ J. 2016 Feb 25;80(3):650-6. doi: 10.1253/circj.CJ-15-1119. Epub 2016 Jan 20. PubMed PMID: 26794153.

8: Barik R, Nemani L. Comment on "Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions". Indian Heart J. 2015 Nov-Dec;67(6):621-2. doi: 10.1016/j.ihj.2015.08.021. Epub 2015 Oct 26. PubMed PMID: 26702708; PubMed Central PMCID: PMC4699973.

9: Iqbal J, Verheye S, Abizaid A, Ormiston J, de Vries T, Morrison L, Toyloy S, Fitzgerald P, Windecker S, Serruys PW. DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. EuroIntervention. 2015 Oct 15;11(6). pii: 20150130-01. doi: 10.4244/EIJY15M10_04. [Epub ahead of print] PubMed PMID: 26465374.

10: Gu H, Hua K, Li W, Wang Y, Yang J. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. Int J Cardiol. 2015 Dec 15;201:552-60. doi: 10.1016/j.ijcard.2015.02.097. Epub 2015 Feb 28. PubMed PMID: 26334379.

11: Masawa T, Abe S, Toyoda S, Sakuma M, Nasuno T, Kageyama M, Tokura M, Koizumi S, Taguchi I, Inoue T. Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy. Heart Vessels. 2015 Aug 14. [Epub ahead of print] PubMed PMID: 26271923.

12: Garcia-Gutierrez JC, Palacios-Rodríguez JM, Cordova-Correa HG, Becerra-Laguna CA, López-López HA, Salinas Aragón MA, García-Bonilla J. [Experience with the use of the bio-active stent coated with titanium nitric oxide compared with zotarolimus-eluting stent: experience of a unit medical high specialty]. Arch Cardiol Mex. 2016 Jan-Mar;86(1):18-25. doi: 10.1016/j.acmx.2015.06.001. Spanish. PubMed PMID: 26256255.

13: Kakefuda Y, Sato A, Watabe H, Aihara H, Nishina H, Noguchi Y, Hoshi T, Aonuma K. Efficacy of Endeavor zotarolimus-eluting stent implantation for the treatment of very late stent thrombosis with late-acquired incomplete stent apposition after sirolimus-eluting stent implantation. Heart Vessels. 2015 Jul 29. [Epub ahead of print] PubMed PMID: 26219730.

14: Ji MS, Jeong MH, Ahn YK, Kim SH, Kim YJ, Chae SC, Hong TJ, Seong IW, Chae JK, Kim CJ, Cho MC, Rha SW, Bae JH, Seung KB, Park SJ, Hur SH; Korea Acute Myocardial Infarction Registry Investigators. Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis. Int J Cardiol. 2015 Nov 15;199:53-62. doi: 10.1016/j.ijcard.2015.07.010. Epub 2015 Jul 7. PubMed PMID: 26186631.

15: Kim BK, Shin DH, Hong MK, Park HS, Rha SW, Mintz GS, Kim JS, Kim JS, Lee SJ, Kim HY, Hong BK, Kang WC, Choi JH, Jang Y; CTO-IVUS Study Investigators. Clinical Impact of Intravascular Ultrasound-Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Biolimus-Eluting Stent Implantation: Randomized Study. Circ Cardiovasc Interv. 2015 Jul;8(7):e002592. doi: 10.1161/CIRCINTERVENTIONS.115.002592. PubMed PMID: 26156151.

16: Song PS, Hahn JY, Kim DI, Song YB, Choi SH, Choi JH, Ryu DR, Hur SH, Jeong JO, Park HS, Kim HS, Gwon HC. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome. Eur J Intern Med. 2015 Sep;26(7):521-7. doi: 10.1016/j.ejim.2015.06.014. Epub 2015 Jul 4. PubMed PMID: 26153337.

17: Bahuleyan CG, Krishna Kumar VV, Babu S. Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions. Indian Heart J. 2015 May-Jun;67(3):233-8. doi: 10.1016/j.ihj.2015.03.014. Epub 2015 May 13. PubMed PMID: 26138180; PubMed Central PMCID: PMC4495589.

18: Rothman M. Resolute zotarolimus eluting stent for treatment of long coronary lesions. Indian Heart J. 2015 May-Jun;67(3):194-5. doi: 10.1016/j.ihj.2015.05.007. Epub 2015 Jun 13. PubMed PMID: 26138172; PubMed Central PMCID: PMC4495596.

19: Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015 Jun;8(6):e002230. doi: 10.1161/CIRCINTERVENTIONS.114.002230. PubMed PMID: 26047993; PubMed Central PMCID: PMC4495878.

20: Burzotta F, Summaria F, Latib A, De Vita M, Fantoni C, Benedetto S, Turturo M, Larosa C, Manzoli A, Trani C. Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions. Catheter Cardiovasc Interv. 2015 Apr 24. doi: 10.1002/ccd.25954. [Epub ahead of print] PubMed PMID: 25914397.